Corporate History

Corporate History

The history of Daito dates back to 1942, when its predecessor was founded as a control company in charge of the export of Toyama-made home medicines. In 2020, Daito marked the 10th anniversary of its listing on the Tokyo Stock Exchange.
Toward the centenary of our founding, we will make sustained efforts to grow to be a company that can be always the first choice of customers.

1942- 1975Foundation phase

  • Daito’s predecessor was established as a control company in charge of the export of Toyama-made home medicines to Southeast Asian countries, where many Japanese lived at that time.
  • After the end of WWII, the Company began to manufacture drugs for home delivery services and then started wholesaling active pharmaceutical products (APIs).
  • In the 1960s, the Company opened sales offices in Tokyo and Osaka to establish a nationwide sales network.
  • After the start of universal health insurance coverage in Japan in 1961, healthcare services permeated the nation.
  • 1942
    • Daitoa Pharmaceutical Trade Control Company Ltd. established
  • 1948
    • Renamed as Daito Trading Co., Ltd.
  • 1949
    • Started manufacturing drugs for home delivery services
  • 1950
    • Established an API Wholesale Division and started selling APIs
  • 1971
    • Established a new research laboratory in Toyama City
Research laboratory soon after its establishment

1976- 2000Development phase

  • The Company expanded into new businesses in line with market needs and development.
  • In the 1970s, in response to the growth of the Japanese ethical drug market, the Company began to manufacture generic drugs and APIs, both of which are now its core products.
  • In the 1980s, as part of its efforts toward business expansion, the Company began to manufacture OTC drugs and started manufacturing intermediates for new drugs on a contract basis.
  • 1976
    • Started manufacturing generic ethical drugs
  • 1979
    • Started manufacturing APIs
  • 1985
    • Started manufacturing OTC drugs
  • 1987
    • Made Daiwa Pharmaceutical Co., Ltd. a partly owned subsidiary
  • 1989
    • Started manufacturing intermediates for new drugs on a contract basis
  • 1991
    • Renamed as Daito Pharmaceutical Co., Ltd. (the Company’s current name)
  • 1993
    • Established the Third Formulation Building
  • 1999
    • Established the Third API Building
Daito APIs and formulation products
OTC drugs
  • Over-the-counter drugs available at pharmacies and drug stores without prescriptions written by doctors
Daiwa Pharmaceutical Co., Ltd.

2001- 2011Growth phase

  • The Company’s ethical drug contract manufacturing business steadily expanded its scale thanks in part to the enforcement of the revised Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices in 2005.
  • The Japanese government implemented measures to promote more widespread use of generic drugs in order to minimize the increase in national medical expenditure.
  • The Company enhanced and added its manufacturing facilities in line with increasing demand and achieved significant growth in sales of generic drugs and APIs.
  • Amid its business growth, the Company was listed on the Tokyo Stock Exchange.
  • 2007
    • Established the Fifth API Building
      Acquired Daiwa Pharmaceutical Co., Ltd. as a wholly owned subsidiary
  • 2008
    • Established Daito Pharmaceuticals America, Inc. in Illinois, the U.S.
      Established the Sixth Formulation Building
  • 2010
    • Listed on the Second Section of the Tokyo Stock Exchange
  • 2011
    • Shifted to the First Section of the Tokyo Stock Exchange
    • Daito Pharmaceuticals America, Inc.
Fifth Formulation Building
Fifth API Building
Listed on the Second Section of the Tokyo Stock Exchange

2012to the presentExpansion phase

  • The Japanese government's measures to promote more widespread use of generic drugs made progress, allowing the Company to grow remarkably.
  • The Company began to devote greater efforts to global expansion and conducted activities based at Daito Pharmaceuticals America, Inc. to boost the export of generic formulation products.
  • In China, the Company acquired Daito Pharmaceutical (China) Co., Ltd. as a subsidiary to optimize the manufacturing system.
  • The Company is also making an increased commitment to the high-potent drug business as a new business field.
  • 2012
    • Acquired Anhui Nanobiotechnology Development Co., Ltd. as a subsidiary (current name: Daito Pharmaceutical (China) Co., Ltd.)
  • 2014
    • Established a Formulation Building at Daito Pharmaceutical (China) Co., Ltd.
      Established the Seventh Formulation Building (for the manufacture of high-potent drugs)
  • 2015
    • Shifted from a company with a board of statutory auditors to a company with an audit and supervisory committee
      Established the Sixth API Building
  • 2017
    • Established a High-potent Drug R&D Center
  • 2018
    • Established the Eighth Formulation Building (for the manufacture of high-potent drugs)
  • 2021
    • Established the Quality Assurance Building
  • 2022
    • Moved to the prime market due to the review of the market classification of the Tokyo Stock Exchange.
      Established the Seventh API Building
  • 2022
    • Established the Seventh API Building
Formulation Building of Daito Pharmaceutical Co., Ltd.
Eighth Formulation Building (for high-potent drugs)
High-potent Drug R&D Center
Quality Assurance Building
Seventh API Building
Company Profile